Skip to main content
OpenTrials
Completed

NCT Number: NCT07474415

Controlled Trial of Gastric Electrical Stimulation in Children

This study evaluates whether gastric electrical stimulation (GES) improves symptoms in children with severe nausea and vomiting that have not responded to standard treatments. GES is a therapy that delivers small electrical pulses to the stomach to help improve stomach function and reduce symptoms. In this study, children underwent temporary gastric electrical stimulation using a pacing lead placed through a nasogastric tube. The stimulation device was turned OFF for four days and then ON for four days, while participants remained blinded to the stimulation status. Symptoms and tolerance to oral nutrient intake were measured at baseline and during each study phase. The goal of the study was to determine whether active stimulation improves symptoms and nutrient intake compared with the sham period.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Gastroparesis Digestive System Diseases Functional Dyspepsia Gastrointestinal Diseases Nausea Neurologic Manifestations Paralysis Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive Stomach Diseases Vomiting Vomiting Syndrome

Age range

Up to 21 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Nationwide Children's Hospital

Columbus, Ohio, 43205, United States

About this study

Children and adolescents with severe nausea and vomiting that do not respond to medical therapy represent a challenging clinical population. Gastric electrical stimulation (GES) has been used as a treatment option for patients with refractory symptoms, but controlled trials in children are limited.

This single-blinded, sham-controlled clinical trial evaluated the short-term effects of temporary gastric electrical stimulation in pediatric patients with refractory nausea and vomiting. Participants underwent placement of a temporary pacing lead through a nasogastric tube connected to an external stimulator. After placement, the stimulator remained OFF for the first four days followed by ON for the next four days. Participants were blinded to the stimulation status.

Baseline data included demographic characteristics, medical history, nutritional status, and symptom assessments using the Symptom Monitor Worksheet (SMW). Participants also completed a nutrient drink test to evaluate tolerance to oral intake. Symptom scores and nutrient drink test volumes were reassessed at the end of each study phase.

The primary objective of the study was to evaluate changes in nausea and vomiting symptoms during sham and active stimulation phases. Secondary objectives included evaluating changes in symptom severity and frequency across gastrointestinal symptoms and assessing tolerance to nutrient intake during the study periods.

This study aims to better understand whether gastric electrical stimulation may improve symptoms and oral intake in children with refractory nausea and vomiting and to inform future therapeutic approaches for this population.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age < 21 years
  • History of chronic nausea and vomiting refractory to medical therapy for at least 12 months
  • Symptoms severe enough to impact overall condition (e.g., weight loss or need for dietary modification)
  • Ability of participant and/or parent/guardian to provide informed consent/assent

Exclusion criteria

  • Mechanical obstruction of the gastrointestinal tract.
  • Diagnosis of an eating disorder
  • Psychiatric condition deemed by the medical team to pose a safety concern for study participation
  • Inability of the participant to communicate symptoms
  • Inability of the participant or parent/guardian to read or speak English

Treatment and study plan

Temporary Gastric Electrical Stimulation

Device

Participants underwent placement of a temporary gastric pacing lead through a nasogastric tube connected to an external gastric electrical stimulator. The device was used to deliver gastric electrical stimulation during the active phase of the study. During the sham phase the device remained OFF, while during the active phase electrical stimulation was delivered to the stomach. The intervention was used to evaluate the effects of gastric electrical stimulation on symptoms of nausea and vomiting and tolerance to oral nutrient intake in children with refractory symptoms.

Other names: Gastric pacing, Temporary gastric stimulation, Gastric electrical neuromodulation

Primary outcomes

  1. Change in Symptom Monitor Worksheet (SMW) Score

    Time frame: Baseline, Day 5 (end of sham phase), and Day 9 (end of active stimulation phase)

    The Symptom Monitor Worksheet (SMW) is used to assess frequency and severity of upper gastrointestinal symptoms, including nausea and vomiting. SMW scores were collected at baseline, at the end of the sham phase (stimulator OFF), and at the end of the active stimulation phase (stimulator ON) to evaluate changes in symptoms during gastric electrical stimulation.

Secondary outcomes

  1. Change in Maximum Tolerated Volume During Nutrient Drink Test

    Time frame: Baseline, end of sham phase (Day 5), and end of active stimulation phase (Day 9)

    The nutrient drink test measures tolerance to oral nutrient intake. Participants consumed a standardized nutrient liquid until reaching maximum tolerated fullness. The maximum tolerated volume (mL) was recorded at baseline, at the end of the sham phase (stimulator OFF), and at the end of the active stimulation phase (stimulator ON) to evaluate changes in gastric tolerance associated with gastric electrical stimulation.

Sponsors and collaborators

Lead sponsor

Nationwide Children's Hospital

Other

Registry information

Official study title

Prospective, Controlled Trial of Gastric Electrical Stimulation in Children With Nausea and Vomiting

Important dates

Study start
2019
Primary completion
2024
Study completion
2025
First posted
Mar 16, 2026
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.